

26/04/2023

ASX Announcement

Tissue Repair (“TR”) announces changes to board of directors

The Company is pleased to announce the appointment of Dr Michael Silberberg, MD MBA as a non-executive director. Dr Silberberg is currently Global Therapeutic Area Head, Facial Aesthetics, Medical Affairs at AbbVie, Inc.

At the same time the Company thanks Max Johnston and Craig Stamp who resign today, having played a key role in guiding it through its initial public offer and submission of its End of Phase 2 application to the FDA for its intended program of works for TR-987®.

Tissue Repair Limited (ASX: TRP, the Company or TR) is pleased to announce that it has appointed Dr Michael Silberberg as a non-executive director.

Dr Silberberg is a twenty-year veteran of the biotech industry, which he entered after nearly a decade as a practising physician and surgeon.

He is currently the Global Therapeutic Area Head, Facial Aesthetics for Abbvie, based in England. Prior to that he spent nine years working for Allergan in a variety of senior roles, culminating as Executive Medical Director, Aesthetics, International and Global Plastic Surgery Therapeutic Area Lead after starting as Director, Medical Affairs, Australia/NZ.

He holds an MBA from the UCLA Anderson School of Management, where he was a Venture Fellow, and has an MD from Cornell University and AB from Brown University.

“I am pleased to join Tissue Repair at this exciting point in its progress with its clinical trials and commencing commercialisation of its aesthetic product,” said Dr Silberberg.

“I am excited at the appointment of Dr Silberberg to TRs Board and the depth of insight he will bring to both TR’s clinical and aesthetics strategies, drawing from his impressive career and domain expertise,” said Tissue Repair founder and executive director, Tony Charara.

“The Company is very grateful to Max Johnston and Craig Stamp for their efforts both pre and post IPO, contributing to the strong position the company finds itself in with both TR-987® and TR Pro+™, TR’s two flagship products utilising the Glucoprime® technology platform. We wish them the best in their future ventures,” said Tissue Repair chairman, Jack Lowenstein.

Subject to Shareholder approval, Dr Silberberg will be granted 392,753 unlisted options under the Company’s Long Term Incentive Plan, exercisable at \$1.15 and expiring 27 September 2036, which will be subject to the following vesting conditions:

- (i) 98,188 options vesting 12 months from the date of his appointment;



Tissue Repair Ltd

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566

- (ii) 294,565 options vesting monthly pro-rata over the next 36 months following the anniversary of his appointment

Please see attached profile of Dr Silberberg.

For further information in relation to this release please contact Darryl Reed at darryl.reed@trtherapeutics.com 0419 557 663.

This announcement has been approved for release by TRP's board.

About Tissue Repair

Tissue Repair Limited (ASX:TRP) is an advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering a Phase 3 program in chronic wounds for its lead drug candidate TR-987[®], with a secondary focus on commercialising TR Pro+[™] a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. The Company's longer-term strategy is to commercialise its propriety Glucoprime[®] API to treat a variety of wounds and skin conditions.



Dr. Michael Silberberg

Dr. Silberberg has over 35 years of experience working in healthcare, pharmaceuticals and medical devices. He currently serves in the role of Global Strategy Head, Medical Affairs for Allergan Aesthetics, an AbbVie company. Michael joined Allergan in 2011 as Medical Director for Australia and New Zealand, overseeing the facial aesthetic, ophthalmic and neurologic business. In 2015, he transitioned to the role of Therapeutic Area Medical Director, Aesthetics, APAC based in Singapore, before relocating to the UK as Executive Medical Director, Aesthetics, International. In 2020, he was promoted to the role of Global Strategy Head, Medical Affairs for the Facial Aesthetic franchise.

Prior to joining Allergan, Michael worked at Novartis Australia, Medical Affairs, covering a broad portfolio of products across transplant medicine, cardiology, anti-infectives, and rheumatology. Prior to this, he served in the role of Director Physician Services, at DaVita, Inc, a California-based renal care services provider.

Dr Silberberg is a Board Certified Otolaryngologist/Head and Neck Surgeon and Facial Plastic Surgeon. He completed his General Surgery training at The New York Hospital/Cornell University, and his Otolaryngology residency at Manhattan Eye, Ear & Throat Hospital (MEETH). In his final year, he served as Chief Resident of the Otolaryngology service at New York Hospital, Lenox Hill Hospital and MEETH, and Head and Neck Fellow at Memorial Sloan-Kettering Cancer Center.

Michael has a Medical Degree from Cornell University Medical College, where he was awarded the JA Moore prize in Otolaryngology, and was named a Barr Scholar and Papanicolaou Fellow. He also has an MBA in Finance and Entrepreneurship from the Anderson School at UCLA, where he served as Venture Fellow. He graduated magna cum laude from Brown University with an AB, Biomedicine.

Dr Silberberg is the author of multiple scientific publications in the field of aesthetic medicine. In his downtime, Michael is an avid adventurer and travel and wildlife photographer.

